Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial

IMPORTANCE: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in preventing stroke and all-cause death while causing significantly fewer major bleeds. To establish the value pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Cowper, Patricia A., Sheng, Shubin, Lopes, Renato D., Anstrom, Kevin J., Stafford, Judith A., Davidson-Ray, Linda, Al-Khatib, Sana M., Ansell, Jack, Dorian, Paul, Husted, Steen, McMurray, John J. V., Steg, P. Gabriel, Alexander, John H., Wallentin, Lars, Granger, Christopher B., Mark, Daniel B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814979/
https://ncbi.nlm.nih.gov/pubmed/28355434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.0065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados